May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?. (July 2020)

• Record Type: Journal Article
• Authors: Adamowicz, Jan; Juszczak, Kajetan; Drewa, Tomasz
• Is Part Of: Medical hypotheses. Volume 140(2020)
• Publication Date: 2020-07
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Medicine; Periodicals; 610
• DOI: 10.1016/j.mehy.2020.109751
• Languages: English
• ISSNs: 0306-9877

Abstract

Abstract: COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males.